Changes in reimbursement to bring profits for branded generics in CIS markets
Most of the Commonwealth of Independent States (CIS) markets do not have modern reimbursement policies, but the countries in question have recently been working in order to improve their drug policies, notes Poland-based market research firm PMR.
In Russia, the Pharma 2020 plan is being implemented in order to improve the quality and accessibility of locally produced drugs. Ukraine has implemented a pilot program for reference pricing which is regarded as a major step toward reforming the system. Kazakhstan has also updated its lists of reimbursed drugs. As a result, PMR expects further growth in the generic drug subgroup, along with healthy development in the arena of original drugs, with compound annual growth rate (CAGR) figures of 15 and 14%, respectively, between 2012 and 2014 for these groups.
Ukraine and Kazakhstan witness most substantial increases in generics
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze